Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...

Within 10 years of Crohn's disease diagnosis, up to 50% of people will require surgery, with ileocaecal or ileocolonic resection being the most common procedure.1 Surgery is not curative and disease ...

OPUVIZ is one of the first wave aflibercept biosimilars in Europe OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's partnership EC ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...

Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) ...

Stocks rebounded after last week’s slide as Treasuries stabilized after 10-year yields approached 4.5%, with traders keeping ...